259 related articles for article (PubMed ID: 32960139)
1. Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors.
Perez-Santos M
Pharm Pat Anal; 2020 Sep; 9(5):149-154. PubMed ID: 32960139
[TBL] [Abstract][Full Text] [Related]
2. Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1.
Chen W; Pandey M; Sun H; Rolong A; Cao M; Liu D; Wang J; Zeng L; Hunter A; Lin S
MAbs; 2021; 13(1):1914359. PubMed ID: 33870864
[TBL] [Abstract][Full Text] [Related]
3. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR
Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858
[TBL] [Abstract][Full Text] [Related]
4. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
Salama AK; Moschos SJ
Ann Oncol; 2017 Jan; 28(1):57-74. PubMed ID: 28177433
[TBL] [Abstract][Full Text] [Related]
5. Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy.
Bazhin AV; Amedei A; Karakhanova S
Front Immunol; 2018; 9():2878. PubMed ID: 30568661
[No Abstract] [Full Text] [Related]
6. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
7. Atypical autoimmune adverse effects with checkpoint blockade therapies.
Friedman CF; Snyder A
Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
[No Abstract] [Full Text] [Related]
8. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?
Simmet V; Eberst L; Marabelle A; Cassier PA
Ann Oncol; 2019 Nov; 30(11):1751-1759. PubMed ID: 31435659
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
11. New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.
Christodoulou MI; Zaravinos A
Crit Rev Immunol; 2019; 39(5):379-408. PubMed ID: 32422018
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of immune checkpoint blockade for brain metastases.
Harary M; Reardon DA; Iorgulescu JB
CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
[No Abstract] [Full Text] [Related]
14. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
15. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule.
Berezhnoy A; Sumrow BJ; Stahl K; Shah K; Liu D; Li J; Hao SS; De Costa A; Kaul S; Bendell J; Cote GM; Luke JJ; Sanborn RE; Sharma MR; Chen F; Li H; Diedrich G; Bonvini E; Moore PA
Cell Rep Med; 2020 Dec; 1(9):100163. PubMed ID: 33377134
[TBL] [Abstract][Full Text] [Related]
16. Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
Rotte A
J Exp Clin Cancer Res; 2019 Jun; 38(1):255. PubMed ID: 31196207
[TBL] [Abstract][Full Text] [Related]
17. Crystallographic approaches to study the interaction modes of PD-1- and CTLA-4-blocking antibodies.
Nomura N; Nomura Y; Sato Y; Iwata S
Methods Enzymol; 2019; 629():383-399. PubMed ID: 31727250
[TBL] [Abstract][Full Text] [Related]
18. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
Hahn AW; Gill DM; Pal SK; Agarwal N
Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
[TBL] [Abstract][Full Text] [Related]
19. Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?
De Silva P; Aiello M; Gu-Trantien C; Migliori E; Willard-Gallo K; Solinas C
Int J Cancer; 2021 Jul; 149(1):31-41. PubMed ID: 33252786
[TBL] [Abstract][Full Text] [Related]
20. Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649.
Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Millán-Pérez Peña L; Rosas-Murrieta NH
Expert Opin Ther Pat; 2019 Dec; 29(12):921-924. PubMed ID: 31627712
[No Abstract] [Full Text] [Related]
[Next] [New Search]